Democrats in the US House of Representatives began what they said would be a wide-ranging investigation into how the US pharmaceutical industry sets prices, moving quickly on an issue where there appears to be accord with the White House.
The US House Committee on Oversight and Reform asked for detailed information about pricing practices from a dozen companies on specific medications, including bestsellers such as AbbVie Inc’s Humira and Amgen Inc’s Enbrel, which are used to treat autoimmune diseases; Pfizer Inc’s pain drug Lyrica; and Sanofi SA’s diabetes treatment Lantus.
Also under scrutiny are medications available in generic formulations, including AstraZeneca PLC’s cholesterol medicine Crestor and Teva Pharmaceuticals Industries Ltd’s multiple sclerosis treatment Copaxone.
“For years, drug companies have been aggressively increasing prices on existing drugs and setting higher launch prices for new drugs while recording windfall profits,” committee chairman Elijah Cummings said. “The goals of this investigation are to determine why drug companies are increasing prices so dramatically, how drug companies are using the proceeds and what steps can be taken to reduce prescription drug prices.”
Drug manufacturers have been under increasing pressure over the cost of their medications. In the past week, US lawmakers on both sides of the aisle have proposed legislation to rein in drug prices.
The pressure has not yet curtailed soaring costs, as drug companies have in the past few weeks boosted US list prices on hundreds of treatments.
Pharmaceutical companies have defended their practices by saying the cost of developing new therapies is high. Some drugmakers have promised to try to increase transparency around drug costs by posting more information about their pricing practices online, among other measures.
The desire to contain high prescription drug costs is a rare area of partisan agreement in Washington.
US Secretary of Health and Human Services Alex Azar last week tweeted that “prices must come down,” praising Merck & Co, Gilead Sciences Inc and Amgen for lower prices.
Neither Merck nor Gilead were sent letters by the committee, according to a list posted on the panel’s Web site.
Shares of contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) came under pressure yesterday after a report that Apple Inc is looking to shift some orders from the Taiwanese company to Intel Corp. TSMC shares fell NT$55, or 2.4 percent, to close at NT$2,235 on the local main board, Taiwan Stock Exchange data showed. Despite the losses, TSMC is expected to continue to benefit from sound fundamentals, as it maintains a lead over its peers in high-end process development, analysts said. “The selling was a knee-jerk reaction to an Intel-Apple report over the weekend,” Mega International Investment Services Corp (兆豐國際投顧) analyst Alex Huang
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is expected to remain Apple Inc’s primary chip manufacturing partner despite reports that Apple could shift some orders to Intel Corp, industry experts said yesterday. The comments came after The Wall Street Journal reported on Friday that Apple and Intel had reached a preliminary agreement following more than a year of negotiations for Intel to manufacture some chips for Apple devices. Taiwan Institute of Economic Research (台灣經濟研究院) economist Arisa Liu (劉佩真) said TSMC’s advanced packaging technologies, including integrated fan-out and chip-on-wafer-on-substrate, remain critical to the performance of Apple’s A-series and M-series chips. She said Intel and Samsung
POWER BUILDUP: Powered by Nvidia’s B200 Blackwell chips, the data center would support MediaTek’s computing power demand and business growth, the company said Smartphone chip designer MediaTek Inc (聯發科) yesterday launched a new artificial intelligence (AI) data center with a maximum capacity of 45 megawatts to meet its rising demand for computing power required to develop new advanced chips for AI applications. The company has completed the first-phase computing power buildup at the data center in Miaoli County’s Tongluo Township (銅鑼), providing 15 megawatts of capacity to support its research and development (R&D) capabilities, despite an industrywide shortage of key components, MediaTek said. Supply constraints have plagued a wide range of key components, including memory chips, solid-state drives, power supply units and central
IMAGE SENSORS: The Japanese company would be the controlling shareholder of the venture, with development and production lines to be set up in Kumamoto Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday said it has signed a non-binding memorandum of understanding (MOU) with Sony Semiconductor Solutions Corp to create a joint venture to develop and produce next-generation images sensors. The partnership seeks to explore and address emerging opportunities in physical artificial intelligence (AI) applications, such as automotive and robotics, paving the way for innovations and expanded technological advancements, TSMC said in a statement. Sony would be the majority and controlling shareholder of the joint venture, the statement said, adding that the company would set up development and production lines in its newly constructed fab in Kumamoto Prefecture’s
RSS